Skip to main navigation

Manage Cookie Consent

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

Privacy and Cookie Notice {title} {title}

Home
About
Pipeline
Investors
Contact

News & Events

Company Overview
News & Events
- News Releases
- Events & Presentations
Stock Information
Financial Information
Corporate Governance
IR Resources
- Email Alerts
- Contact IR

News Category

Year

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Oct 20, 2026

PDF Version

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Oct 14, 2026

PDF Version

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Oct 06, 2026

PDF Version

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Sep 22, 2026

PDF Version

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

Sep 10, 2026

PDF Version

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Sep 08, 2026

PDF Version

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million

Aug 28, 2026

PDF Version

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome

Aug 28, 2026

PDF Version

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 14, 2026

PDF Version

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

Aug 07, 2026

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 27

Past Events

There are no past events available at this time.

Presentations

Corporate Overview 2 MB

Subscribe

Sign up for alerts to stay up to date on Quoin Pharmaceuticals.

News:

Oct 20, 2026

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Oct 14, 2026

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

2026 © Quoin Pharmaceuticals, Inc. Privacy Policy